|

PD-1 Inhibitors Clinical Trials

7 actively recruiting trials

Also known as: Nivolumab, Pembrolizumab

Pipeline

Phase 1: 1Phase 2: 3

Top Sponsors

  • Ming-Yuan Chen2
  • Sun Yat-sen University1
  • Sichuan University1
  • Shandong Cancer Hospital and Institute1
  • Quanli Gao1

Indications

  • Cancer7
  • Liver Disease2
  • Recurrent or Metastatic Nasopharyngeal Carcinoma2
  • Liver Cancer2
  • Hepatocellular Carcinoma2

Other7 trials

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
N/A
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Phase 2
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Phase 1
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
N/A
The Immune Assessment of PD-1 Antibody Therapy in Tumor

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.